based oral vaccines for anthrax
Salmonella Salmonella A vaccine for the prevention of anthrax, including a live, attenuated and at least one nucleotide sequence encoding anthrax protective antigen (PA) or a fragment thereof and a nonlethal mutated form of anthrax lethal factor (LF) or a fragment thereof. In another implementation,...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Salmonella Salmonella A vaccine for the prevention of anthrax, including a live, attenuated and at least one nucleotide sequence encoding anthrax protective antigen (PA) or a fragment thereof and a nonlethal mutated form of anthrax lethal factor (LF) or a fragment thereof. In another implementation, the vaccine is constituted for the prevention of anthrax and at least one additional pathogen, as including a live, attenuated and at least one nucleotide sequence encoding at least a fragment of a nonlethal mutated form of anthrax lethal factor (LF) and at least one nucleotide sequence encoding at least a fragment of an antigen of an additional pathogen. Vaccines of such types can be administered to stimulate antibody response in a subject, whereby the antibody response confers immunity to the subject. |
---|